Fig. 1: Four 2-weeks cycles with galunisertib lead to viral reactivation in blood. | Nature Communications

Fig. 1: Four 2-weeks cycles with galunisertib lead to viral reactivation in blood.

From: TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo

Fig. 1

A Schematic representation of the study and sampling schedule. B Plasma VL in blood for each macaque throughout the study. The longer black line indicates the period on ART, while the 4 small black lines indicate the start and end of each galunisertib cycle. C Enlarged plasma VL for all macaques during galunisertib therapy. Green bars indicate galunisertib cycles. Source data are provided as a Source Data file. Image from BioRender.

Back to article page